Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Medrol Dosepak for Outpatient Total Knee Arthroplasty

Rush University Medical Center · NCT05097976

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
420
US sites recruiting
1
Study start
March 1, 2022
Record last updated
July 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the efficacy of an oral methylprednisolone taper on acute postoperative pain, function, opioid consumption, nausea, and complications following outpatient total knee arthroplasty (TKA). We hypothesize that administration of an oral methylprednisolone taper starting on postoperative day 1 (POD 1) following TKA will be associated with improved pain and decreased opioid use, nausea, and complications at POD1-7, as compared to similar patients who receive placebo. Additionally, those taking methylprednisolone will report decreased pain and greater objective functional outcomes at 3 and 6 weeks postoperatively as compared to controls.

Being studied: Methylprednisolone; Placebo

Conditions: Total Knee Arthroplasty

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Any patient undergoing primary TKA with a diagnosis of osteoarthritis

•≥ 18 years old

  • Willingness to undergo randomization

Exclusion Criteria

  • Reported chronic corticosteroid or opiate use
  • Suspected or confirmed periprosthetic joint infection
  • Revision TKA
  • Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, or post-traumatic arthritis
  • American Society of Anesthesiologists (ASA) score ≥ 4
  • Reported history of liver disease, renal disease, or diabetes mellitus
  • Current systemic fungal infection or other local infection
  • Immunocompromised or immunosuppressed
  • Current peptic ulcer disease
  • History of hypothyroidism, psychosis, heart failure, myasthenia gravis, ocular herpes simplex virus, or systemic sclerosis
  • Women with reported current pregnancy
  • Known hypersensitivity to methylprednisolone

•≤ 18 years old

  • Inability to take oral medications
  • Unable to provide consent

Recruiting US locations

  • Rush Oak Brook Outpatient Center

    Oak Brook, IL 60523

    Site contact: Anne DeBenedetti, BA · 3124322468 · anne.debenedetti@rushortho.com

Study contacts (from the official record)

  • Anne DeBenedetti · 3124322468 · anne.debenedetti@rushortho.com
All pain studies in Illinois →
Medrol Dosepak for Outpatient Total Knee Arthroplasty (NCT05097976) | Bored Studies